Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
Corroborated by 1 source from 1 publisher
globalhealth1d ago
TL;DR
According to finance.yahoo.com, bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more attractive risk-reward profile for investors.